2-Arylvinylquinoline Antimalarials for Chloroquine-Resistant Malaria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of drug-resistant malaria parasites threatens the effectiveness of current antimalarial therapies, necessitating the development of new compounds with different modes of action to combat chloroquine-resistant strains and support combination treatments.
Innovation Solution
Development of potent, low nanomolar 2-arylvinylquinolines that exhibit fast-acting antimalarial activity against the asexual blood stage parasites and transmission-blocking potential, with compounds like 24 demonstrating excellent selectivity and in vivo efficacy without noticeable toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If artemisinin-based combination therapy (ACT) is used, then malaria burden is reduced, but cost becomes prohibitive for low-income countries
Solution Approach 1:
The patent modifies the chemical structure of chloroquine by introducing an aminoferrocene group to create ferroquine, which maintains antimalarial efficacy while potentially reducing cost. The molecular parameters are changed to overcome resistance and improve therapeutic properties
Solution Approach 2:
The patent creates a hybrid molecule combining the quinoline scaffold of chloroquine with the ferrocene group, forming a composite structure that leverages the advantages of both components: the antimalarial activity of chloroquine and the stability and resistance-breaking properties of ferrocene
2Reliability
If chloroquine is used, then it is effective against all types of human malaria parasites, but resistance develops due to PfCRT mutations
Solution Approach 1:
The patent changes the chemical parameters of chloroquine by adding an aminoferrocene group, which alters how the drug interacts with the PfCRT transporter and the digestive vacuole environment, thereby overcoming resistance mechanisms while maintaining efficacy
Solution Approach 2:
The patent converts the harmful effect of PfCRT mutations that cause resistance into a beneficial outcome by designing a molecule whose enhanced lipophilicity and cationic character at physiological pH allow it to bypass or overcome the resistance mechanism, turning the resistance pathway into a route for improved drug delivery
3Reliability
If quinoline scaffold compounds are developed, then transmission-blocking properties are achieved, but structural complexity increases
Solution Approach 1:
The patent designs the ferroquine molecule to perform multiple functions: it acts as an effective blood-stage antimalarial agent and simultaneously provides transmission-blocking activity against gametocytes, reducing the need for separate compounds for different stages of the parasite lifecycle
Data Source
AI summary
Antimalarial compounds of the formula: in which n is 1 or 2; X is C or N; R1 is a moiety comprising a secondary amine and a tertiary amine joined by a C2 to C4 alkyl chain; and R2 is CF3, F, or H, or an analog, combination, derivative, prodrug, stereoisomer, or pharmaceutically acceptable salt thereof. Pharmaceutical compounds including the antimalarial compounds. Methods of treating or preventing malaria comprising administering an effective amount of the antimalarial compounds.